Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2013
10/16/2013CN103349657A Risperidone film-shaped preparation
10/16/2013CN102973531B Levetiracetam medicine composition and preparation method thereof
10/16/2013CN102813879B Preparation method for traditional Chinese medicine for treating blood stasis type insomnia
10/16/2013CN102793901B Preparation method of traditional Chinese medicine for treating abdominal distension type insomnia
10/16/2013CN102698226B Chinese medicine for treating postherpetic neuralgia
10/16/2013CN102669196B Plant composition for repelling mosquitoes and method for preparing same
10/16/2013CN102631350B Compound preparation of quetiapine fumarate and lurasidone
10/16/2013CN102614315B Compound sleeping-improving capsule and preparation method thereof
10/16/2013CN102614122B Ketorolac tromethamine nasal cavity spraying agent and preparation method thereof
10/16/2013CN102579409B Donepezil transdermal patch
10/16/2013CN102552841B Traditional Chinese medicine for treating apoplexy sequelae
10/16/2013CN102083799B Benzimidazole derivatives used as FXR agonists
10/16/2013CN102068697B Opiates painkiller and opiate receptor antagonist-containing medicinal composition
10/16/2013CN102065861B Use of trans-4-((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine for treating cognitive deficits
10/16/2013CN101935301B Modulators of ATP-binding cassette transporters
10/16/2013CN101784543B Indole and indazole compounds as an inhibitor of cellular necrosis
10/16/2013CN101605905B Method for glycosylation of flavonoid
10/16/2013CN101602796B Selenium-containing active polypeptide, preparing method and application thereof
10/16/2013CN101528733B 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin-2-one as CBL' receptor modulators
10/16/2013CN101490055B Spirocyclic azaindole derivatives
10/16/2013CN101208345B (S)-N-methylnaltrexone, processes for its synthesis and its pharmaceutical use
10/15/2013US8558009 Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine
10/15/2013US8557864 Agent having neurotrophic factor-like activity
10/15/2013US8557857 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
10/15/2013US8557855 Methods of using ryanodine antagonists in treating neural injury
10/15/2013US8557851 Combinations of flupirtine and sodium channel inhibiting substances for treating pains
10/15/2013US8557845 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
10/15/2013US8557842 Cocaine analogs and methods of preparation and uses thereof
10/15/2013US8557796 Substituted 1-oxa-2,8-diaza-spiro [4,5] dec-2-ene derivatives and related treatment methods
10/15/2013US8557785 In vivo production of small interfering RNAS that mediate gene silencing
10/15/2013US8557546 Recombinant human G-CSF dimer and use thereof for the treatment of neurological diseases
10/15/2013US8557286 Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix
10/15/2013US8557271 Drug depot implantable within a joint
10/15/2013US8557256 Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
10/15/2013US8557240 Method for the treatment of inflammatory disorders
10/15/2013US8557233 Probiotic bifidobacterium strains
10/15/2013CA2697256C Cyclopropyl amide derivatives
10/15/2013CA2667936C Amorphous form of n-{2-fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo [1,5-a]pyrimidin-7-yl]-phenyl}-n-methyl-acetamide
10/15/2013CA2623160C Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
10/15/2013CA2615676C N(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof
10/15/2013CA2522319C N-[(piperazinyl)hetaryl]arylsulfonamide compounds and derivatives thereof with affinity for the dopamine d3 receptor
10/15/2013CA2487732C Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
10/15/2013CA2410762C Feline hepatocyte growth factor
10/15/2013CA2373721C Compounds that bind her2
10/10/2013WO2013152350A1 Myricanol derivatives and uses thereof for treatment of neurodegenerative diseases
10/10/2013WO2013152291A1 Cell therapy technology to deliver radio-protective peptides
10/10/2013WO2013152105A1 Pharmaceutical compositions for combination therapy
10/10/2013WO2013151832A1 Tetrahydropyrrolothiazine compounds
10/10/2013WO2013151729A1 Compositions, methods and assays comprising amylin or amlyin analogs for abeta-peptide mediated disorders
10/10/2013WO2013151281A1 Composition containing mori cortex radicis extract as active ingredient for preventing or treating depression
10/10/2013WO2013150529A2 Indole, indoline derivatives, compositions comprising them and uses thereof
10/10/2013WO2013150303A1 Stem cell microparticles
10/10/2013WO2013150295A1 Food supplement to support brain function
10/10/2013WO2013150173A1 New alpha2 adrenoceptor agonists
10/10/2013WO2013150150A1 An h3 receptor antagonist for use in the treatment of alzheimer's disease
10/10/2013WO2013150117A1 Radiotracer, in particular for alzheimer's disease
10/10/2013WO2013149997A1 Substituted tricyclic compounds with activity towards ep1 receptors
10/10/2013WO2013149996A1 Substituted tricyclic compounds with activity towards ep1 receptors
10/10/2013WO2013149976A1 Indole-pyrimidine derivatives and their therapeutic uses
10/10/2013WO2013149800A1 Carboxamide compounds and their use as calpain inhibitors v
10/10/2013WO2013149580A1 Timosaponin compounds
10/10/2013WO2013149506A1 Chimeric peptide based on opioid peptide biphalin and neuropeptide ff and synthesis and use thereof
10/10/2013WO2013149470A1 Bisbenzylisoquinoline compound or pharmaceutically acceptable salt treatment and new application in easing depression symptom
10/10/2013WO2013149384A1 Brain atrophy prevention agent
10/10/2013WO2012160713A8 Learning and memory improver
10/10/2013US20130267601 Method for prevention of alzheimer's disease
10/10/2013US20130267595 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
10/10/2013US20130267477 Method of using nutritional compounds dihydroquercetin (taxifolin) and arabinogalactan in combination with dihydroquercetin (taxifolin) to reduce and control cardiometabolic risk factors associated with metabolic syndrome and hypercholesterolemia
10/10/2013US20130266553 Albumin Fusion Proteins
10/09/2013EP2647697A1 Method for producing hematopoietic stem cells using pyrazole compound
10/09/2013EP2647638A1 Substituted tricyclic compounds with activity towards ep1 receptors
10/09/2013EP2647634A1 Indole-pyrimidine derivatives and their therapeutic uses
10/09/2013EP2647630A1 Biguanide derivative compound
10/09/2013EP2647628A1 Substituted tricyclic compounds with activity towards ep1 receptors
10/09/2013EP2647619A1 Novel compound and medical use thereof
10/09/2013EP2647386A1 Lissencephaly therapeutic agent
10/09/2013EP2647377A1 Use of an h3 receptor antagonist for the treatment of alzheimer's disease
10/09/2013EP2647374A1 Nutritional compositions including beta-hydroxy-beta-methylbutyrate for regulating transcription factors
10/09/2013EP2646454A2 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
10/09/2013EP2646444A1 Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes
10/09/2013EP2646443A1 Kat ii inhibitors
10/09/2013EP2646441A2 Carbocycle-substituted purine and 7-deazapurine compounds
10/09/2013EP2646438A1 3-hetaryl-substituted pyrrolo[2,3-b]pyridine derivatives as pdk1 inhibitors
10/09/2013EP2646437A1 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds
10/09/2013EP2646421A1 7-nitro-5-phenyl-1-(pyrrolidin-1-ylmethyl)-1h-benzo[e][1,4]diazepin-2(3h)-one and other benzodiazepine derivatives
10/09/2013EP2646417A1 Kat ii inhibitors
10/09/2013EP2646415A1 Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
10/09/2013EP2646019A1 Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
10/09/2013EP2646001A2 Formulation of lacosamide
10/09/2013EP2645997A2 Once daily formulation of lacosamide
10/09/2013EP2645994A2 Formulations comprising methylthioninium chloride
10/09/2013CN103347856A Multifunctional nitroxide derivatives and uses thereof
10/09/2013CN103347522A 透皮贴剂 Transdermal patches
10/09/2013CN103347519A Dosing regimen for sedation with CNS 7056 (remimazolam)
10/09/2013CN103347495A Combination of opioid agonist and opioid antagonist in treatment of parkinson's disease
10/09/2013CN103343075A Health-keeping and healthcare medicinal liquor and preparation method thereof
10/09/2013CN103342758A Low molecular weight chondroitin sulfate and application thereof in preparation of anti-alzheimer disease medicine
10/09/2013CN103342757A Amphipathic chondroitin sulfate derivative and preparation method and application thereof
10/09/2013CN103342729A Caffeoyl substituted pentacyclic triterpenoid derivatives and purpose thereof
10/09/2013CN103342700A 11[beta]-hydroxysteroid dehydrogenase type 1 inhibitor
1 ... 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 ... 1833